CYAD Celyad SA

8.9
+0.03  (+0%)
Previous Close 8.88
Open 9.4
Price To Book 2.71
Market Cap 124,086,862
Shares 13,942,344
Volume 34,532
Short Ratio
Av. Daily Volume 39,858
Stock charts supplied by TradingView

NewsSee all news

  1. Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting

    Results from ongoing, dose-escalation alloSHRINK Phase 1 trial demonstrate absence of graft-versus-host disease for first-in-class, non-gene edited allogeneic CAR-T candidate, CYAD-101, when administered concurrently

  2. Celyad Highlights Abstracts from mCRC Clinical Program Released for SITC 34th Annual Meeting

    Management to host webcast on Saturday, Nov. 9, at 12:35 p.m. ET/ 6:35 p.m. CET MONT-SAINT-GUIBERT, Belgium, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage

  3. Celyad Announces October and November 2019 Investor Conference Schedule

    MONT-SAINT-GUIBERT, Belgium, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies,

  4. Celyad to Present Update on mCRC Clinical Program at the 2019 SITC Annual Meeting

    Poster presentations to highlight allogeneic and autologous NKG2D-based CAR-T therapies for the treatment of advanced metastatic colorectal (mCRC) cancers MONT-SAINT-GUIBERT, Belgium, Oct. 02, 2019 (GLOBE NEWSWIRE) --

  5. Celyad Announces Closing of $20 Million Global Offering

    MONT-SAINT-GUIBERT, Belgium, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data did not meet primary endpoint
C-Cure - Chart 1 trial
Chronic Heart Failure secondary to ischemic cardiomyopathy
Phase 1 data due at ASH December 9, 2019, 6 p.m ET.
CYAD-01 - THINK
Various cancers - solid and hematologic cancers
Phase 1 further data due 1H 2020.
CYAD-101 - alloSHRINK
Colorectal cancer
Phase 1 data presented at SITC November 8, 2019.
CYAD-01 and FOLFOX - SHRINK
Colorectal cancer
Phase 1 data due at ASH December 9, 2019, 6 p.m ET.
CYAD-01 and chemotherapy (DEPLETHINK)
AML or myelodysplastic syndrome (MDS)
Phase 1 trial to commence early 2020 with data due mid-2020.
CYAD-02
Relapsed/refractory Acute myeloid leukemia (AML) and Myelodysplastic Syndrome (MDS)

Latest News

  1. Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting

    Results from ongoing, dose-escalation alloSHRINK Phase 1 trial demonstrate absence of graft-versus-host disease for first-in-class, non-gene edited allogeneic CAR-T candidate, CYAD-101, when administered concurrently

  2. Celyad Highlights Abstracts from mCRC Clinical Program Released for SITC 34th Annual Meeting

    Management to host webcast on Saturday, Nov. 9, at 12:35 p.m. ET/ 6:35 p.m. CET MONT-SAINT-GUIBERT, Belgium, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage

  3. Celyad Announces October and November 2019 Investor Conference Schedule

    MONT-SAINT-GUIBERT, Belgium, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies,

  4. Celyad to Present Update on mCRC Clinical Program at the 2019 SITC Annual Meeting

    Poster presentations to highlight allogeneic and autologous NKG2D-based CAR-T therapies for the treatment of advanced metastatic colorectal (mCRC) cancers MONT-SAINT-GUIBERT, Belgium, Oct. 02, 2019 (GLOBE NEWSWIRE) --

  5. Celyad Announces Closing of $20 Million Global Offering

    MONT-SAINT-GUIBERT, Belgium, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today

  6. Horizon Discovery Group plc: Results for the Six Months Ended 30 June 2019

    RNS Horizon Discovery Group plcResults for the Six Months Ended 30 June 2019 Cambridge, UK, 16 September 2019: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or "the Company"), a global

  7. Celyad Announces Pricing of $20.0 Million Global Offering

    MONT-SAINT-GUIBERT, Belgium, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today

  8. Celyad Announces Launch of Proposed Global Offering

    MONT-SAINT-GUIBERT, Belgium, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies,

  9. Be The Match BioTherapies® and Celyad Announce Collaboration to Advance Development of Allogeneic CAR-T Therapies

    Alliance will support the clinical progression of Celyad's non-gene edited allogeneic CAR-T candidates Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell

  10. Celyad Successfully Doses First Patient with CYAD-01 Produced with OptimAb Manufacturing Process

    MONT-SAINT-GUIBERT, Belgium, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies,

  11. Celyad to Participate in Upcoming September 2019 Conferences

    MONT-SAINT-GUIBERT, Belgium, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies,

  12. Celyad Reports Half Year 2019 Financial Results and Second Quarter Business Highlights

    MONT-SAINT-GUIBERT, Belgium, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today